Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
San Diego, CA
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
San Diego, CA
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
San Diego, CA
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Santa Ana, CA
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Torrance, CA
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Torrance, CA
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Norwalk, CT
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Norwalk, CT
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Leesburg, FL
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Leesburg, FL
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Melbourne, FL
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Melbourne, FL
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Miami, FL
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Oakland Park, FL
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Oakland Park, FL
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Orlando, FL
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Atlanta, GA
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Atlanta, GA
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Hoffman Estates, IL
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Glen Burnie, MD
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Glen Burnie, MD
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
St. Louis, MO
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Nashua, NH
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Nashua, NH
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Willingboro, NJ
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Willingboro, NJ
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Brooklyn, NY
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Rochester, NY
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Staten Island, NY
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Staten Island, NY
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Hickory, NC
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Hickory, NC
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Beachwood, OH
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Beachwood, OH
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Cleveland, OH
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Allentown, PA
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Allentown, PA
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Norristown, PA
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Norristown, PA
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Philadelphia, PA
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Houston, TX
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Irving, TX
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Irving, TX
Click here to add this to my saved trials
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated:  6/5/2014
Novartis Investigative Site
mi
from
Salt Lake City, UT
Relapse Prevention Study in Patients With Schizophrenia
A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Status: Enrolling
Updated: 6/5/2014
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA Medical Center, Birmingham, AL
mi
from
Birmingham, AL
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA Medical Center, Birmingham, AL
mi
from
Birmingham, AL
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA Medical Center, Tuscaloosa, AL
mi
from
Tuscaloosa, AL
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA Medical Center, Tuscaloosa, AL
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Central Arkansas VHS Eugene J. Towbin Healthcare Center, Little Rock, AR
mi
from
No. Little Rock, AR
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Central Arkansas VHS Eugene J. Towbin Healthcare Center, Little Rock, AR
mi
from
No. Little Rock, AR
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA Long Beach Healthcare System, Long Beach, CA
mi
from
Long Beach, CA
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA Long Beach Healthcare System, Long Beach, CA
mi
from
Long Beach, CA
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA Palo Alto Health Care System, Palo Alto, CA
mi
from
Palo Alto, CA
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA Palo Alto Health Care System, Palo Alto, CA
mi
from
Palo Alto, CA
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA San Diego Healthcare System, San Diego, CA
mi
from
San Diego, CA
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA San Diego Healthcare System, San Diego, CA
mi
from
San Diego, CA
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
mi
from
West Haven, CT
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
mi
from
West Haven, CT
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Washington DC VA Medical Center, Washington, DC
mi
from
Washington,
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Washington DC VA Medical Center, Washington, DC
mi
from
Washington,
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA Medical Center, Miami
mi
from
Miami, FL
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA Medical Center, Miami
mi
from
Miami, FL
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Richard L. Roudebush VA Medical Center, Indianapolis, IN
mi
from
Indianapolis, IN
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Richard L. Roudebush VA Medical Center, Indianapolis, IN
mi
from
Indianapolis, IN
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA Boston Healthcare System Brockton Campus, Brockton, MA
mi
from
Brockton, MA
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA Boston Healthcare System Brockton Campus, Brockton, MA
mi
from
Brockton, MA
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA Central Western Massachusetts Healthcare System, Leeds, MA
mi
from
Leeds, MA
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA Central Western Massachusetts Healthcare System, Leeds, MA
mi
from
Leeds, MA
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
New Mexico VA Health Care System, Albuquerque, NM
mi
from
Albuquerque, NM
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
New Mexico VA Health Care System, Albuquerque, NM
mi
from
Albuquerque, NM
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Franklin Delano Roosevelt Campus of the VA Hudson Valley Health Care System, Montrose, NY
mi
from
Montrose, NY
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Franklin Delano Roosevelt Campus of the VA Hudson Valley Health Care System, Montrose, NY
mi
from
Montrose, NY
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
mi
from
New York, NY
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
mi
from
New York, NY
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC
mi
from
Salisbury, NC
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC
mi
from
Salisbury, NC
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Cincinnati VA Medical Center, Cincinnati, OH
mi
from
Cincinnati, OH
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Cincinnati VA Medical Center, Cincinnati, OH
mi
from
Cincinnati, OH
Click here to add this to my saved trials